This article is more than 5 years old. Information may no longer be current.
Beth Israel Deaconess Medical Center names cancer center director
Click Here to Manage Email Alerts
Manuel Hidalgo, MD, PhD, has been named director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and chief of the division of hematology-oncology at Beth Israel Deaconess Medical Center.
Hidalgo’s work in experimental cancer therapy and tumor model development has led to key advances in the treatment of pancreatic cancer.
Manuel Hidalgo
He previously served as director of the clinical research program and vice director of translational research at Centro Nacional de Investigaciones Oncologicas in Spain. He also holds faculty positions at University CEU San Pablo and Johns Hopkins University.
“Dr. Hidalgo’s expertise perfectly complements our work and mission,” Pier Paolo Pandolfi, MD, PhD, director of Beth Israel Deaconess Medical Center’s Cancer Center and Cancer Research Institute, said in a press release. “The research platform developed by his team is now used for drug screening, biomarker development and the creation of personalized therapies. It is consistent with our approach, in which experimental drugs are tested in a ‘mouse hospital setting’ in parallel with human clinical trials.”
Hidalgo is a founder of the Pancreatic Cancer Research Team, a private nonprofit cooperative group dedicated to rapid drug development in pancreatic cancer. He previously served as associate professor and co-director of the gastrointestinal cancer program at Johns Hopkins.
“I am honored to join BIDMC, which is a global leader in bringing together clinicians and scientists to promote excellence in cancer care,” Hidalgo said in a press release. “I share BIDMC’s philosophy that research and patient care inform and complement one another, and that the skill and expertise of both disciplines will be required to win the fight against all types of cancer.”